


## Remarks

### I. Preliminary Amendment


Applicants have amended the first page of the specification by adding a sentence to reflect priority claims.

Applicants have canceled the original claims and have added a new claim in this preliminary amendment. Support for the new claims can be found in the original claims, and on pages 6-16 of the specification. Applicants have indicated that A is a phenyl,



support for which can be found in Examples 1-37. Further, the phrase “R<sup>k</sup> include the following ring systems...” has been moved to new dependent claim 54 and changed to “wherein A<sup>1</sup> is selected from the group consisting of:”, the phrase “the following heteroaryls include...” has been moved into new dependent claims 55-56 and changed to “wherein A<sup>1</sup> is selected from the group consisting of:”, and the phrase “A<sup>1</sup>-Z<sub>2</sub> of the present invention include...” has been moved into new dependent claim 57 and changed to “wherein A<sup>1</sup>-Z<sub>2</sub> is selected from the group consisting of:” to more specifically point out and clarify the invention. The phrases “alternatively, Z<sub>1</sub>-Z<sub>2</sub> may further include...” and “optionally the group X-Y can contain a moiety...” have been removed to more specifically point out and clarify the invention. The phrase “wherein R<sup>5</sup> and R<sup>7</sup> are defined above,” was added after the phrase “wherein Y<sup>2</sup> is selected from the group consisting of alkyl; cycloalkyl; bicycloalkyl; aryl; monocyclic heterocycles;” to more specifically point out and clarify the invention.

The moieties labeled “B” in claims 55 and 57 have been re-labeled B<sup>1</sup> to B<sup>18</sup> to more specifically point out and clarify the invention. In claim 55, in the moiety



B<sup>9</sup> = CH<sub>2</sub>, O, CO, S, CF<sub>3</sub>, SO<sub>2</sub>, NR


R' = OR, OH, Me n = 1

“or 2 ”, “R” has been changed “R<sup>1</sup>” to reflect the substituent shown in the moiety.

The Applicants do not believe that any additional fees are due; however, the Office has the authority to charge the Applicants' Deposit Account for any fees that are presently due, or any fees that will become due. Please charge any appropriate fees to Deposit Account No. 19-1025.

If the Examiner believes a telephonic interview with Applicant's representative would aid in the prosecution of this application, he or she is cordially invited to contact Applicant's representative at the below listed number.

Respectfully submitted,



Rachel A. Polster  
Agent for Applicants  
Reg. No. 47,004  
314-274-7354 (St. Louis)

PHARMACIA CORPORATION  
Corporate Patent Law Department  
P.O. Box 1027  
Chesterfield, Missouri 63006